(S-088) A pediatric PBPK model of atropine gel to predict atropine levels in children with neurological disorders after administration to oral cavity

Madison Parrot, B.S. – Molecular Pharmaceutics – University Of Utah; Nancy Murphy – Pediatrics – University Of Utah; Venkata Yellepeddi – Clinical Pharmacology – University Of Utah

Enter your core abstract text here using the suggested layout. Abstracts are text only: No figures/tables. Do not paste author or affiliation information in the body of your abstract. Max character count not including spaces for abstract body is 2800.: Objectives
Sialorrhea, or excessive salivation, is a chronic and serious problem in children with cerebral palsy (CP) and neurodevelopmental disorders.1-5 Sialorrhea occurs in up to 60% of children with CP and has serious health consequences, including recurrent pulmonary infections and progressive lung disease.6,7-9 Sialorrhea reduces social interaction and self-esteem, and can significantly diminish the quality of life in children with CP.10-17 Current treatments are often invasive or poorly tolerated.6 Due to ease of administration, limited side effect profile, and the rapidity of a drying effect, sublingual atropine eye drops are frequently used off-label to treat sialorrhea.3 To improve upon this, we developed a mucoadhesive atropine gel (US Patent Appl. No: US20230149306A1) that increases oral residence time and reduces dosing frequency and side effects.18 Following a completed FDA-approved Phase I trial confirming safety and pharmacokinetics (PK) in adults, this study aims to scale and verify an oral cavity physiologically-based pharmacokinetic (PBPK) model for pediatric use and develop an optimal dosing regimen for a Phase II efficacy trial.

Methods
The adult oral cavity PBPK model of atropine gel was developed using the Oral Cavity Compartmental Absorption and Transit (OCCATTM) module of GastroPlus®, SimulationsPlus, USA. The OCCATTM PBPK model has six compartments and specific oral parameters. The adult oral cavity model was optimized using the PK data obtained from our Phase I study of atropine gel in healthy adults.19 The pediatric oral cavity PBPK model of atropine gel was scaled from the adult model using Population Estimates for Age-Related PhysiologyTM (PEAR PhysiologyTM) module of GastroPlus® and used to simulate the PK of atropine gel at dose ranges 0.003 to 0.222 mg/kg in virtual populations of children (N=1000) representing the following age groups: infants (29 days to < 2 years), children (2 to < 12 years), and adolescents (12 to 21 years). The optimal dose of atropine gel in pediatric patients for this efficacy study was selected using the minimum efficacy target concentration of 1.46 ng/mL20 and maximum toxic target concentration of 61 ng/mL.21

Results
The adult oral cavity PBPK model of atropine gel accurately predicted the observed data from the Phase I PK study of atropine gel in adult healthy volunteers. The predicted PK parameters of atropine Cmax, Tmax, AUC0-24h, and AUC0-inf after administration to the oral cavity as a gel formulation were all within ±30% of the observed values. The pediatric oral cavity PBPK model simulations showed that for doses up to 0.222 mg/kg of atropine oral gel, atropine levels did not reach the maximum toxicity target level (61 ng/mL), and a minimum dose of 1 mg/day is required to reach the efficacy target (1.46 ng/mL) to see a 50% reduction in sialorrhea.

Conclusion
The mucoadhesive atropine gel was determined to be safe, with optimal PK, in a healthy adult population, as demonstrated by the Phase I clinical trial.19 The development and validation of the adult oral cavity PBPK model for atropine gel were successfully completed and validated and was successfully scaled to pediatrics. The dose range for atropine, 0.003 to 0.222 mg/kg, is safe in pediatric patients with sialorrhea.

Citations: [1] Walshe M, Smith M, Pennington L. Interventions for drooling in children with cerebral palsy. Cochrane Database Syst Rev. Nov 14 2012;11:CD008624. doi:10.1002/14651858.CD008624.pub3
[2] Dias BLS, Fernandes AR, Maia HSF. Treatment of drooling with sublingual atropine sulfate in children and adolescents with cerebral palsy. Arquivos de Neuro-Psiquiatria. 2017;75(5):282-287. doi:https://dx.doi.org/10.1590/0004-282X20170033
[3] Petkus KD, Noritz G, Glader L. Examining the Role of Sublingual Atropine for the Treatment of Sialorrhea in Patients with Neurodevelopmental Disabilities: A Retrospective Review. J Clin Med. Aug 11 2023;12(16)doi:10.3390/jcm12165238
[4] Bekkers S, Pruijn IMJ, van der Burg JJW, et al. Surgery versus botulinum neurotoxin A to reduce drooling and improve daily life for children with neurodevelopmental disabilities: a randomized controlled trial. Dev Med Child Neurol. Nov 2021;63(11):1351-1359. doi:10.1111/dmcn.14924
[5] Reid SM, Westbury C, Chong D, Johnstone BR, Guzys A, Reddihough DS. Long-term impact of saliva control surgery in children with disability. J Plast Reconstr Aesthet Surg. Jul 2019;72(7):1193-1197. doi:10.1016/j.bjps.2019.02.020
[6] AACPDM Care Pathways, September 2016. https://www.aacpdm.org/publications/care-pathways/sialorrhea-in-cerebral-palsy. (Accessed on June, 25, 2023).
[7] Postma AG, Heesters M, van Laar T. Radiotherapy to the salivary glands as treatment of sialorrhea in patients with parkinsonism. Mov Disord. Dec 2007;22(16):2430-5. doi:10.1002/mds.21752
[8] Leibner J, Ramjit A, Sedig L, et al. The impact of and the factors associated with drooling in Parkinson's disease. Parkinsonism Relat Disord. Aug 2010;16(7):475-7. doi:10.1016/j.parkreldis.2009.12.003
[9] Bergmans B, Clark V, Isaacson SH, Baumer T. Recommendations for a paradigm shift in approach to increase the recognition and treatment of sialorrhea in Parkinson's disease. Clin Park Relat Disord. 2023;9:100223. doi:10.1016/j.prdoa.2023.100223
[10] Chang SC, Lin CK, Tung LC, Chang NY. The association of drooling and health-related quality of life in children with cerebral palsy. Neuropsychiatr Dis Treat. 2012;8:599-604. doi:10.2147/NDT.S39253
[11] van der Burg J, Jongerius P, van Limbeek J, van Hulst K, Rotteveel J. Drooling in children with cerebral palsy: a qualitative method to evaluate parental perceptions of its impact on daily life, social interaction, and self-esteem. Int J Rehabil Res. Jun 2006;29(2):179-82. doi:10.1097/01.mrr.0000194395.64396.f1
[12] Van der Burg JJ, Jongerius PH, Van Hulst K, Van Limbeek J, Rotteveel JJ. Drooling in children with cerebral palsy: effect of salivary flow reduction on daily life and care. Dev Med Child Neurol. Feb 2006;48(2):103-7. doi:10.1017/S0012162206000235
[13] van der Burg JJ, Jongerius PH, van Limbeek J, van Hulst K, Rotteveel JJ. Social interaction and self-esteem of children with cerebral palsy after treatment for severe drooling. Eur J Pediatr. Jan 2006;165(1):37-41. doi:10.1007/s00431-005-1759-z
[14] Dickinson HO, Parkinson KN, Ravens-Sieberer U, et al. Self-reported quality of life of 8-12-year-old children with cerebral palsy: a cross-sectional European study. Lancet. Jun 30 2007;369(9580):2171-2178. doi:10.1016/S0140-6736(07)61013-7
[15] Varni JW, Burwinkle TM, Sherman SA, et al. Health-related quality of life of children and adolescents with cerebral palsy: hearing the voices of the children. Dev Med Child Neurol. Sep 2005;47(9):592-7.
[16] Houlihan CM, O'Donnell M, Conaway M, Stevenson RD. Bodily pain and health-related quality of life in children with cerebral palsy. Dev Med Child Neurol. May 2004;46(5):305-10. doi:10.1017/s0012162204000507
[17] Bjornson KF, McLaughlin JF. The measurement of health-related quality of life (HRQL) in children with cerebral palsy. Eur J Neurol. Nov 2001;8 Suppl 5:183-93. doi:10.1046/j.1468-1331.2001.00051.x
[18] Yellepeddi VK, inventor; Compositions and Methods for Treating Sialorrhea. United States 2023.
[19] Parrot M, Yathavan B, Averin O, et al. Clinical pharmacokinetics of atropine oral gel formulation in healthy volunteers. Clinical and Translational Science. 2024-03-01 2024;17(3)doi:10.1111/cts.13753
[20] Mubaslat O, Fitzpatrick M, McLachlan AJ, Lambert T. Pharmacokinetics and Effects on Saliva Flow of Sublingual and Oral Atropine in Clozapine-Treated and Healthy Adults: An Interventional Cross-Over Study. Psychiatry and Clinical Psychopharmacology. 2022;32(1):17-27. doi:10.5152/pcp.2022.21221
[21] Amitai Y, Almog S, Singer R, Hammer R, Bentur Y, Danon YL. Atropine poisoning in children during the Persian Gulf crisis. A national survey in Israel. JAMA. Aug 5 1992;268(5):630-2.

Keywords: pediatric, drug delivery, clinical trial design